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Mutations in the cardiac ryanodine receptor (RYR2) are the leading cause for catecholaminergic polymorphic ventricular
tachycardia (CPVT). In this study, we evaluated antiarrhythmic eﬃcacy of carvedilol and ﬂecainide in CPVT patient-speciﬁc
induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) carrying diﬀerent mutations in RYR2. iPSC-CMs were
generated from skin biopsies of CPVT patients carrying exon 3 deletion and L4115 or V4653F mutation in RYR2 and of a
healthy individual. Ca2+ kinetics and drug eﬀects were studied with Fluo-4 AM indicator. Carvedilol abolished Ca2+
abnormalities in 31% of L4115F, 36% of V4653F, and 46% of exon 3 deletion carrying CPVT cardiomyocytes and ﬂecainide 33%,
30%, and 52%, respectively. Both drugs lowered the intracellular Ca2+ level and beating rate of the cardiomyocytes signiﬁcantly.
Moreover, ﬂecainide caused abnormal Ca2+ transients in 61% of controls compared to 26% of those with carvedilol. Carvedilol
and ﬂecainide were equally eﬀective in CPVT iPSC-CMs. However, ﬂecainide induced arrhythmias in 61% of control cells.
CPVT cardiomyocytes carrying the exon 3 deletion had the most severe Ca2+ abnormalities, but they had the best response to
drug therapies. According to this study, the arrhythmia-abolishing eﬀect of neither of the drugs is optimal. iPSC-CMs provide a
unique platform for testing drugs for CPVT.
1. Introduction
Human-induced pluripotent stem cells (hiPSCs) can be gen-
erated from patients’ somatic cells [1]. The technique makes
research of vital organs, such as the heart, available in vitro.
Primary adult cardiomyocytes (CMs) stop beating in vitro
after a few hours of culture, but iPSC-derived CMs can be cul-
tured for months with proper beating behavior. The hiPSC-
derived CMs carry the same genome as the patient they were
generated from. The production of disease-speciﬁc hiPSC
lines allows disease modeling and drug development in vitro.
Catecholaminergic polymorphic ventricular tachycardia
(CPVT) is a severe inherited cardiac disease in structurally
normal hearts, and it is associated with increased risk of sud-
den cardiac death [2].The prevalence of CPVT is approxi-
mately 1 : 10,000, and the prognosis is bad: mortality rate
without treatment is as high as 35% by the age of 30. At the
age of 40, 80% of patients have had symptoms. CPVT patients
experience arrhythmias during emotional or exercise-
induced adrenergic stress. Adrenaline binding into β-recep-
tors triggers a signaling cascade via cyclic AMP and protein
kinase A, which results in phosphorylation of key Ca2+ han-
dling proteins at themembrane of the sarcoplasmic reticulum
(SR). In CPVT patients with mutated RYR2, increased Ca2+
concentration inside the SR can result in spontaneous Ca2+
leakage and in arrhythmias. Exercise stress test is used in the
diagnosis of CPVT during which polymorphic ventricular
extra systoles or even tachycardia is often seen in the electro-
cardiograph (ECG).
Majority of CPVT cases arise from mutations in the gene
coding for cardiac ryanodine receptor, RYR2. Other genes are
also implicated in CPVT, but in far lesser extent, for example,
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ANK2, CALM1, CALM2, CASQ2, KCNJ2, SCN5A, TECRL,
andTRDN [2]. RYR2 is the largest known ion channel protein
located at the membrane of the SR. It releases Ca2+ from SR,
which acts as an intracellular Ca2+ storage in CMs, to the cyto-
sol. In physiologically normal condition, L-type Ca2+ chan-
nels (LTCCs) at the T-tubules of the sarcolemma are
activated by an action potential (AP). LTCCs and RYR2s are
located in close proximity to each other creating junctional
complexes. The activation of LTCCs creates an inward ﬂow
of Ca2+ ions into the CM, which in turn activates RYR2s at
the adjacent SR. This phenomenon is known as Ca2+-induced
Ca2+ release (CICR) (Figure 1). CPVT causing mutations in
RYR2 results in gain of function and altered open probabili-
ties of the channel pore and therefore lowered threshold for
store overload-induced Ca2+ release (SOICR) [3]. This spon-
taneous Ca2+ leakage can result in sodium Ca2+ exchanger
(NCX) triggered early and/or delayed afterdepolarizations
(EADs/DADs) and arrhythmias in CMs [4].
Beta-blockers are commonly used in the treatment of
CPVT. These compounds block the β-receptors and thus
inhibit the sympathetic stimulation. Carvedilol is a nonspe-
ciﬁc, combined β1/β2/α-adrenergic blocker, which has been
successfully used in the treatment of chronic heart failure
[5]. For patients who do not respond to beta-blocker therapy,
ﬂecainide has been investigated as an additional option [6, 7].
During the last few years, it has been intensively investigated
by several research groups [8–10]. Flecainide is a class Ic anti-
arrhythmic agent, a sodium channel blocker, which inhibits
inward sodium current via voltage-gated sodium channels
(Nav1.5). Other therapeutic options for CPVT include
implanted cardiac deﬁbrillators and left cardiac sympathetic
denervation. However, present therapeutic options do not
provide complete protection against potentially lethal
arrhythmias, and this is still a clinically relevant problem.
In this study, we evaluate the eﬃcacy of carvedilol and
ﬂecainide in abolishing Ca2+ abnormalities in CPVT
patient-speciﬁc hiPSC-derived CMs carrying diﬀerent muta-
tions in RYR2.
2. Methods
2.1. Patient-Speciﬁc Human iPSC Lines. In this study, four
CPVT hiPSC lines were used carrying the following RYR2
mutations: two lines with exon 3 deletion c.168-301_c.273
+722del1128 (results pooled), one line with point mutation
p.L4115F (c.12343C>T), and another one with point muta-
tion p.V4653F (c.13957G>T). Mutation nomenclature was
based on RYR2 reference sequence NM_001035.2. The loca-
tion of the mutations in the RYR2 amino acid sequence is
illustrated in Figure 2. hiPSC line from a healthy individual
was used as a control cell line. Collection of biopsies for
generating patient-speciﬁc iPSC lines was approved by
the ethical committee of Pirkanmaa Hospital District
(Aalto-Setälä R08070), and written informed consent was
obtained from all the donors. Human iPSC lines were
established by sendai viral (CytoTune® iPS reprogramming
kit, Thermo Fisher Scientiﬁc, Waltham, MA, USA) or ret-
roviral transfection of OCT3/4, SOX2, KLF4, and c-MYC
[1]. The characterization of hiPSC lines is described in
supplementary data (Supplementary Figures 1 and 2).
2.2. Cardiac Diﬀerentiation and Dissociation. Diﬀerentiation
into CMs was carried out by coculturing hiPSCs with murine
visceral endoderm-like (END-2) cells (Professor Mummery,
Humbrecht Institute, Utrecht, The Netherlands) (supple-
mentary data). hiPSCs formed spontaneously beating clusters
after 15 days of coculturing. Beating clusters were cut and iso-
lated with scalpel and dissociated with collagenase A (Roche
Diagnostics). Cells were plated on 12mm round glass cover-
slips coated with 0.1% gelatin.
2.3. Ca2+ Imaging. Ca2+ imaging was conducted 4 to 7 days
after dissociation, when CMs were 23–78 days old. Cells on
a coverslip were loaded with 4μM Fluo-4 AM (Life Technol-
ogies Ltd.) for 30 minutes and deesteriﬁed for 10 minutes in
perfusate medium: (in mM) 137 NaCl, 5 KCl, 0.44 KH2PO4,
20 HEPES, 4.2 NaHCO3, 5 D-glucose, 2 CaCl2, 1.2 MgCl2,
and 1 Na-pyruvate dissolved in H2O. pH of the perfusate
mediumwas adjusted to 7.4 withNaOH. Perfusate was heated
to 37°C with an inline heater SH-27B controlled with a TC-
324B controller unit (Warner Instruments Inc., CT, USA). A
coverslip was attached to a RC-25 imaging chamber (Warner
Instruments Inc.) with a silicon-based compound. Ca2+ kinet-
ics of spontaneously beating CMs were imaged with an
inverted Olympus IX70 microscope using UApo/3400,75NA
20x air objective (Olympus, Tokyo, Japan) and recorded with
ANDOR iXon 885 EM-CCD camera (Andor Technology,
Belfast, Northern Ireland) using 2× 2 binning and synchro-
nized with a Polychrome V light source by a real-time DPS
control unit. Live Acquisition software (TILL Photonics,
Munich, Germany) was used to control light source and cam-
era during recording. Fluo-4 was excited at 490nm wave-
length, and the emission was recorded through Olympus U-
MF2 Alexa 488 band-pass ﬁlter cube (ex.470–495, em.525/
50 nm). Antiarrhythmic evaluation of studied drugs was
assessed by recording Ca2+ transients at baseline (perfusate
only), 3min after 1μM adrenaline incubation and if recorded
transients exhibited Ca2+ abnormalities (Figures 3 and 4),
5min after 0.25μM carvedilol (Sigma) or 10μM ﬂecainide
(Sigma) perfusion at the presence of 1μM adrenaline. All
the recordings were 30 sec long with a sampling rate of 20ms.
2.4. Data Analysis and Statistics. For Ca2+ imaging analysis,
beating single cells or small clusters were selected as regions
of interests (ROI) and background signal was subtracted
using the Live Acquisition software. Recorded Ca2+ traces
were further analyzed with Clampﬁt software version 10.5
(Molecular Devices, USA). The following parameters of the
Ca2+ traces were extracted: ΔF/F0 (where ΔF = F − F0 and
F0 is background subtracted), Ca
2+ transient duration in mil-
liseconds, half-width (Ca2+ transient duration measured at
50% of amplitude) in milliseconds, and frequency in hertz.
Statistical analysis was carried out with SPSS software version
23 (SPSS, Chicago, IL, USA). Comparison within cell lines
(before and after drug administration) was performed with
nonparametric Wilcoxon and between cell lines (cell line to
cell line comparison) with nonparametric Mann–Whitney
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U tests with Dunn-Bonferroni post hoc. P < 0 05 was consid-
ered statistically signiﬁcant.
Ca2+ transients were categorized into seven groups: oscil-
lation (OS), multiple peaks (MP), alternans (AL), plateau
abnormality (PA), low peaks (LP), irregular phase (IP), and
normal (N) (Figure 3). Ca2+ transients were categorized with
the following criteria: oscillation, if there were more than
three peaks in the same event; multiple peaks, if there were
two or three peaks in the same event; alternans, if there were
consistent alternating pattern in the amplitude of six or more
consecutive peaks in the trace; plateau abnormality, if there
was a signiﬁcant disturbance in the rise or decay phase of a
peak (excluding multiple peaks); low peaks, if a single peak
amplitude was 10–90% of the amplitude of a normal peak in
the trace; irregular phase, if the phase was irregular in the
absence of low peaks; and normal, if the trace did not include
any of the aforementioned abnormalities. CPVT phenotype
of the recorded cells was conﬁrmed by the detection of
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Figure 1: Ca2+ overload in the SR during adrenergic stress leads to EADs and DADs causing arrhythmia in CPVT. During rest, depolarization
of the CM membrane by inward current of sodium activates LTCCs leading to CICR and contraction. Adrenergic stimulus (Adr) leads to
phosphorylation of RYR2 and SERCA2a via second messengers of the β-adrenergic pathway (cAMP, PKA) and causes Ca2+ overload in
the SR. Mutations in RYR2 lead to altered threshold for SOICR and spontaneous Ca2+ leak from the SR. Sudden increase in intracellular
Ca2+ activates NCX and causes membrane depolarization leading to EADs and DADs. Carvedilol (CAR) blocks the beta-adrenergic
receptors (βAR) inhibiting the phosphorylation of Ca2+ handling proteins and decreasing the SR Ca2+ load. Flecainide (FLE) inhibits
voltage-gated sodium channel (Nav) and membrane depolarization leading to the inhibition of LTCC and RYR2 indirectly. CICR=Ca
2+-
induced Ca2+ release; SOICR= store overload-induced Ca2+ release; NCX= sodium Ca2+ exchanger; SERCA2a = sarcoplasmic reticulum
Ca2+ ATPase; cAMP= cyclic AMP; PKA=protein kinase A. ∗Both carvedilol and ﬂecainide have a direct inhibiting eﬀect on RYR2.
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Figure 2: Schematic presentation of RYR2 amino acid sequence and the localization of the studied mutations in it. Mutations in RYR2 are
enriched into four clusters (1–4). Modiﬁed from [11].
3Stem Cells International
adrenaline-induced Ca2+ abnormalities. Only cells, which
exhibited arrhythmias after adrenergic stimulation, were
exposed to the drugs. Antiarrhythmic evaluation of studied
drugs was assessed after drug and adrenaline incubation
phases. If all the Ca2+ abnormalities were abolished, recorded
trace was categorized into responder (Supplementary
Figures 3 and 4). If 50% or more of the abnormalities seen
in the adrenaline phase were abolished, trace was
categorized into semiresponder. The rest of the traces were
categorized into nonresponders. Control cells were exposed
to the drugs if the Ca2+ transients were normal after
adrenergic stimulation (healthy phenotype). Proarrhythmic
risk evaluation of the studied drugs in control cells was
assessed after administration of either drugs with adrenaline
and categorizing responses into two groups: normal, which
were completely normal, and drug-induced arrhythmia if
one or more arrhythmic events were present in the trace
(Supplementary Figures 3 and 4).
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Figure 3: Ca2+ transient abnormality types. Normal =N; oscillation =OS; multiple peak =MP; alternans =AL; plateau abnormality = PA; low
peaks = LP; and irregular phase = IP. Multiple peaks is two or three consecutive peaks where the amplitude does not decay to the baseline, and
oscillation is more than three consecutive kinds of these peaks.
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3. Results
3.1. Adrenaline Induced Arrhythmias in CPVT CMs but
Abolished Them in Control Cells. All CPVT CMs exhibited
arrhythmias after three minutes of β-adrenergic stress
(1μM adrenaline), although 25% of L4115F, 28% of
V4653F, and 8% of CMs carrying exon 3 deletion were nor-
mal at the baseline (Figure 4). All control CMs were normal
after three minutes of β-adrenergic stimulus, although 19%
of the cells showed arrhythmias in the baseline (Figure 4).
1μM adrenaline abolished arrhythmias in control CMs but
induced arrhythmias in CPVT CMs (Figure 4). In CPVT
CMs after three minutes of adrenaline incubation, ΔF/F0
was signiﬁcantly (P < 0 05) lower in the oscillation (OS),
multiple peaks (MP), and plateau (PA) abnormal transient
categories than in the normal (N) transients (Supplementary
Figure 5A). In addition, transient duration was signiﬁcantly
(P < 0 05) higher in the OS and MP than in the N in the
presence of adrenaline (Supplementary Figure 5B). In these
two visually most severe abnormality types (OS and MP),
the additional arrhythmic events were the reason for
prolonged Ca2+ peak duration.
3.2. Carvedilol and FlecainideWere Equally Eﬀective in CPVT
Cells. Both carvedilol and ﬂecainide were equally eﬀective
in treating arrhythmias in CPVT CMs. Carvedilol abolished
Ca2+ abnormalities in 31% of L4115F, 36% of V4653F, and
46% of exon 3 deletion and ﬂecainide 33%, 30%, and 52%,
respectively (Figure 4).However,ﬂecainidewas superior abol-
ishing AL type of abnormalities compared to carvedilol
(Table 1). Both drugs lowered ΔF/F0 of all CMs signiﬁcantly
(P < 0 05): carvedilol 12% in control, 21% in L4115F, 16% in
V4653F, and 26% in exon 3 deletion and ﬂecainide 20%,
18%, 21%, and 35%, respectively (Figure 5). The intracellular
Ca2+ was the lowest in CPVT CMs carrying exon 3 deletion,
and the antiarrhythmic eﬀect of the drugs was the best in that
CPVT cell population. Both drugs also lowered the beating
frequency of all CMs signiﬁcantly (P < 0 05): carvedilol 33%
in control, 27% in L4115F, 24% in V4653F, and 39% in exon
3 deletion and ﬂecainide 29%, 33%, 29%, and 46%, respec-
tively. CPVT CMs exhibited 25% OS, 37% MP, 11% AL,
21% PA, 4% LP, and 2% IP type of Ca2+ abnormalities at the
baseline (Table 1). Both drugs abolished most types of
arrhythmias: carvedilol abolished 27% OS, 63% MP, 0%
AL, 19% PA, 33% LP, and 100% IP and ﬂecainide 32%
OS, 51% MP, 27% AL, 20% PA, 57% LP, and 67% IP type
of abnormalities.
3.3. Mutation-Speciﬁc Characteristics. CPVT CMs carrying
exon 3 deletion had the highest incidence of OS (39%) and
MP (46%) abnormalities compared to other patient-speciﬁc
CMs after adrenaline exposure (Figure 4). CPVT CMs carry-
ing V4653F mutation had the highest incidence of AL (28%)
and CMs with L4115F mutation PA (32%), LP (10%), and IP
(6%) abnormalities. The incidence of diﬀerent abnormal
Ca2+ transients varied in CMs carrying diﬀerent mutations.
CMs carrying the RYR2 exon 3 deletion were clearly diﬀerent
compared to the others.
The incidence of PA abnormalities in diﬀerent RYR2
mutant CMs treated with ﬂecainide was 10% in exon 3 dele-
tion, 48% in L4115F, and 40% in V4653F and surprisingly
also 53% in control (Figure 4(b)). Furthermore, both carve-
dilol and ﬂecainide were the most eﬀective in abolishing
arrhythmias in CMs carrying RYR2 exon 3 deletion. In addi-
tion, carvedilol eﬀect on CMs with exon 3 deletion was
dependent of the value of ΔF/F0, which is a measurement of
[Ca2+]i. Responders in this cell population had signiﬁcantly
(P < 0 05) higher intracellular Ca2+ at baseline and after
adrenaline than nonresponders (Supplementary Figure 6A).
Overall, exon 3 deletion had the lowest ΔF/F0 values on
average throughout the experiments (Figure 5).
3.4. Flecainide Caused More Arrhythmias in Control CMs
Than Carvedilol. Flecainide caused arrhythmias in 61%
and carvedilol in 26% of control cells, which had normal
regular transients during adrenaline exposure (Figure 4).
Flecainide caused mostly PA abnormalities (87% of
arrhythmias), whereas carvedilol caused mostly IP abnor-
malities (69% of arrhythmias) (Figure 4). The duration
and half-width of Ca2+ transients were greatly increased
in control CMs after ﬂecainide compared to carvedilol
(Figure 5). Moreover, in control CMs, ﬂecainide lowered
the intracellular Ca2+ of nearly double the amount of carve-
dilol (Figure 5). When comparing normal cells and drug-
induced arrhythmias in the control group at the baseline
and after adrenaline exposure, CMs with ﬂecainide-induced
arrhythmias, duration, and half-width were increased
(Supplementary Figures 6C and 6D). At the baseline,
the diﬀerence in frequency was just bordering statistical
Table 1: Incidence of each calcium abnormality type in all CPVT
CMs after adrenaline stimulation and the percentages of these
arrhythmias abolished by either carvedilol or ﬂecainide.
OS MP AL PA LP IP
CPVT CMs 25% 37% 11% 21% 4% 2%
Carvedilol 27% 63% 0% 19% 33% 100%
Flecainide 32% 51% 27% 20% 57% 67%
MP, LP, and IP type of abnormal transients were abolished quite well by both
drugs, while ﬂecainide was superior in abolishing AL-type abnormalities.
Incidence of LP and IP abnormalities was, however, low in CPVT CMs;
therefore, conclusions should be made with caution.
Figure 4: Incidence of diﬀerent Ca2+ abnormality types in control, L4115F, V4653F, and exon 3 deletion CMs under each condition. (a)
Carvedilol data and (b) ﬂecainide data. Flecainide caused Ca2+ abnormalities in 61% of control cells whereas carvedilol only in 26%. Both
drugs were equally eﬀective in CPVT CMs carrying L4115F mutation. V4653F responded the same way to both drugs as L4115F whereas
in exon 3 deletion, the eﬃcacy of both drugs was higher. Moreover, in the exon 3 deletion CMs, the incidence of oscillations was much
higher than in the others. Donut charts represent the responder groups after drug treatment (adrenaline + drug). BL = baseline;
Adr = 1μM adrenaline; CAR= 0.25 μM carvedilol; FLE = 10μM ﬂecainide; OS = oscillation; MP=multiple peak; AL = alternans;
PA= plateau abnormality; LP = low peak; IP = irregular phase; N = normal; n= amount of CMs studied.
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signiﬁcance but reached signiﬁcance after adrenaline
exposure. CMs with drug-induced arrhythmias had also
slower beating frequency than normal cells (Supplementary
Figure 6E). After ﬂecainide treatment, these diﬀerences
were even more pronounced. At the baseline and after
adrenaline exposure, the control CMs in which carvedilol
caused arrhythmias had higher beating frequency but the
diﬀerence was just bordering the threshold for statistical
signiﬁcance (Supplementary Figure 6B).
4. Discussion
In this study, we wanted to mimic the CPVT disease in vitro
by exposing the hiPSC-derived CMs with adrenaline. CMs
generated fromdiﬀerent patients carrying diﬀerentmutations
in RYR2 showed diﬀerent types of calcium abnormalities.
Beta-blocker carvedilol and class Ic antiarrhythmic agent ﬂe-
cainide were tested in abolishing these arrhythmias. The
patients in the clinic experience arrhythmias under adrener-
gic stress, and earlier study has shown the hiPSC CMs to pro-
vide indicative information of the clinical outcome in drug
study [11]. Carvedilol and ﬂecainide were equally eﬀective
abolishing Ca2+ abnormalities in CPVT CMs, but ﬂecainide
was superior abolishing AL abnormalities. Flecainide also
caused arrhythmias in 61% of control CMswhereas carvedilol
only in 26% of control CMs. CMs with RYR2 exon 3 deletion
were the most responsive to both drug therapies. Further-
more, both drugs lowered the intracellular Ca2+ (ΔF/F0) and
beating frequency of all CMs, but there were mutation-
speciﬁc diﬀerences in Ca2+ abnormality proﬁles.
4.1. Flecainide. Flecainide is thought to have three modes of
action. First, as a class Ic antiarrhythmic agent, it is a strong
sodium channel blocker. During the fast rise of AP phase 0,
depolarization of CM cell membrane takes place and leads
to activation of LTCCs and RYR2. Therefore, inhibition of
INa leads indirectly to inhibition of RYR2 action and there-
fore reduces spontaneous Ca2+ leakage from the SR. Second,
the ability to block INa increases the threshold for EAD- and
DAD-triggered APs in CMs. The third one is debated, but it
is thought that ﬂecainide also has a direct blocking eﬀect on
RYR2. Flecainide has already been showing potential in the
treatment of CPVT in the clinics [6, 7]. Thus, ﬂecainide
was chosen to be tested with our CPVT cell model in vitro.
In this study, ﬂecainide decreased ΔF/F0 in all CMs but we
cannot say if the eﬀect seen was because of direct inhibition
of RYR2 or not. The temporal resolution of the recordings in
this study did not allow reliable analysis of the rise time of
the Ca2+ transients, which could have given indication of
the eﬀect of INa block therefore allowing comparison of that
between each condition.
The debate about whether ﬂecainide has a direct eﬀect
on RYR2 has been recently reviewed [12]. Flecainide eﬀect
on RYR2 could be explained by its eﬀect on some of the
several RYR2 binding regulators. This would explain why
Bannister and coworkers did not see ﬂecainide eﬀect on
RYR2 in their permeabilized mouse myocytes or single-
channel RYR2 models [8]. Moreover, CMs of mouse ori-
gin have a higher beating frequency than those of human
origin and ﬂecainide has beat rate-dependent sodium
channel-blocking eﬀect; thus, it will probably dominate
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Figure 5: Parameters of the Ca2+ traces under each condition. (a) The upper row represents carvedilol data, and (b) the lower row represents
ﬂecainide data. ΔF/F0: Ca2+ peak amplitude; duration: Ca2+ peak duration; half-width: duration at half-maximum amplitude; frequency: the
beating frequency of CMs. Data is shown as averages. BL = baseline; Adr = 1 μM adrenaline; CAR= 0.25 μM carvedilol; FLE = 10μM
ﬂecainide. ∗Statistical signiﬁcance (P < 0 05). Error bars represent standard error of the mean (SEM).
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in mouse models [10]. Contrary to these reports, Wata-
nabe and coworkers and Hilliard and coworkers found
direct action of ﬂecainide on RYR2 in isolated myocytes
from CASQ2 knockout mice [7, 9]. However, based on
our ﬁndings, we cannot exclude mutation-speciﬁc eﬀects
of ﬂecainide in diﬀerent CPVT CMs. Opposing views were
observed by Liu and coworkers with R4496C and Bannis-
ter and coworkers with N4104K mutations in RYR2. Sup-
porting views were studied in wild-type RYR2.
In this current study with control cells, ﬂecainide caused
PA abnormalities (Figure 3) with prolongation of plateau
phase of Ca2+ transients resulting in longer duration and
half-width (Figure 5). This is probably a consequence of
the ability of ﬂecainide to block IKr/hERG [13]: decreased
repolarization rate of CM membrane leads to prolongation
in APD. Prolonged APD results in longer open state of
LTCCs and NCX and longer Ca2+ transient. Furthermore,
the control cells, in which ﬂecainide caused arrhythmias,
had longer duration and half-width of their Ca2+ transients
and slower beating frequency after adrenaline exposure than
the cells, which were normal (Supplementary Figures 6C–
6E). These results go along with the known beat rate
dependency of ﬂecainide’s sodium channel-blocking ability
[14]. 10μM ﬂecainide blocks 80% and 1μM only 20% of
wild-type hERG current in a HEK293 cell model [13].
Adjusting the ﬂecainide concentration more towards the
therapeutic serum levels (0.5–2.4μM) would probably
diminish the percentage of drug-induced arrhythmia in
our current study. The majority of ﬂecainide-induced PA
abnormalities were seen in the decay phase of Ca2+ peaks,
and therefore, the prolonged repolarization caused by
hERG block would explain these. However, besides the
hERG-blocking eﬀect of ﬂecainide, these abnormalities
could be also due to reduced intercellular coupling in small
cell aggregates due to the sodium channel-blocking eﬀect
of ﬂecainide.
The proarrhythmic risk of ﬂecainide has been investi-
gated in the clinical Cardiac Arrhythmia Suppression Trial
(CAST) in the mid-90s. In the CAST, patients treated with
encainide or ﬂecainide had higher mortality rates after
myocardial infarction compared to placebo group [15].
However, another more recent clinical study reported suc-
cessful treatment of CPVT patients without worsening of
exercise-induced ventricular arrhythmias [6]. Class Ic
antiarrhythmic agents are known to be associated with
proarrhythmia and should be used with caution. Flecainide
is contraindicated in structurally abnormal hearts because
it slows conduction velocity in myocardium and possibly
facilitates reentry. Flecainide is typically used to treat
tachycardias, for example, as a rhythm control drug in
paroxysmal atrial ﬁbrillation if no other cardiac diseases
are present.
For this study, ﬂecainide concentration was selected
based on the literature. In the recent study, Preininger and
coworkers showed that 10μM ﬂecainide reduced spontane-
ous Ca2+ waves and Ca2+ spark abnormalities by lowering
ΔF/F0 of these events in CPVT-speciﬁc iPSC-derived CMs
carrying L3741P mutation in RYR2 [16]. They compared
the eﬀect to β-blocker nadolol (10μM) and found ﬂecainide
to be superior. However, they did not see abnormalities in
Ca2+ activity after ﬂecainide treatment in their control cells.
Itzhaki and coworkers tested 10μM ﬂecainide on iPSC
CMs carrying RYR2 M4109R mutation, and it abolished all
DADs during patch-clamp recording [17]. Maizels and
coworkers [18] studied 6μM ﬂecainide in CPVT hiPSC
CMs carrying mutation in CASQ2. In their study, ﬂecainide
abolished 57% of Ca2+ abnormalities in CPVT CMs and
decreased SOICR incidence by 15%. In our study, ﬂecainide
abolished 38% of Ca2+ abnormalities in all CPVT CMs,
which is less compared to others.
4.2. Carvedilol. Beta-blockers can be speciﬁc or nonspeciﬁc
depending of their binding to β- and α-receptors. Binding
to not only β-receptors but also α-receptors gives a beta-
blocker, in addition to its negative inotropic eﬀects on myo-
cardium, a dilative eﬀect on smooth muscle cells of blood
vessels therefore reducing also blood pressure. Carvedilol is
a versatile nonspeciﬁc β1/β2/α-adrenergic blocker used in
the treatment of heart failure [5]. Besides carvedilol, nadolol
is another common nonselective β1/β2-blocker, which is
used in treatment of CPVT. Adrenergic stress leads to phos-
phorylation of key Ca2+ handling proteins, including RYR2,
via the β-adrenergic signaling pathway. Eﬃcacy of beta-
blockers in the treatment of arrhythmias in CPVT is based
on their capability to block this pathway. In addition to its
beta-blocking ability, carvedilol and its derivatives have also
been shown to suppress SOICR in HEK293 cell model by
directly blocking the RYR2 [19, 20]. Therefore, carvedilol
has a double action on CM Ca2+ handling: via β-adrenergic
signaling and RYR2. Therefore, carvedilol could have poten-
tial in the treatment of CPVT, and thus, it was tested with our
CPVT cell model in this study. Also, in the previously men-
tioned study by Maizels and coworkers, 0.3μM carvedilol
abolished 50% of Ca2+ abnormalities in CPVT CMs [18].
Moreover, they reported that carvedilol decreased SOICR
incidence by 37%.
In this study, carvedilol was the most eﬀective in CPVT
CMs carrying RYR2 exon 3 deletion. Interestingly, even
though these CPVT CMs had lower ΔF/F0 compared to
other mutations, the responders in this group had higher
ΔF/F0 than the nonresponders (Supplementary Figure 6A).
Higher ΔF/F0 was favorable considering responsiveness to
the carvedilol therapy in exon 3 deletion CPVT CMs but
not in other mutations. Overall, carvedilol decreased ΔF/F0
in all cell lines but, again, we cannot say if the eﬀect seen
was because of direct inhibition of RYR2 or not. In control
CMs, carvedilol caused arrhythmias in cells, which were
beating faster initially, although this ﬁnding was not
statistically signiﬁcant (Supplementary Figure 6B). This
suggests that in control CMs, in which the spontaneous
beating rate is greatly lowered by carvedilol, the irregular
beating phase will most probably occur since most of the
Ca2+ abnormalities caused by carvedilol were IP type.
In this study, we used 1μM adrenaline concentration,
which is relatively high. It is probable that the β-receptors
were desensitized through the β-arrestin-mediated pathway
during 3min administration. Consequently, the β-receptors
are internalized by endocytosis decreasing the amount of
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available receptors to the drug molecules. It is possible that
due to this reason, we did not see signiﬁcant increase in beat-
ing frequency or changes in duration of calcium transients of
the CMs. The eﬀect of adrenaline is rapid and takes place
after few seconds of administration in vitro. Continuous
recording would be ideal, but the phototoxicity of the ﬂuores-
cent imaging and the adrenaline protocol did not allow a
time frame to capture the wanted eﬀect. The main idea was
to challenge the cells to mimic the adrenergic stress condition
in CPVT. However, if majority of the β-receptors were
desensitized and internalized, the direct eﬀect of carvedilol
on RYR2 could explain the antiarrhythmic eﬃcacy. Carve-
dilol concentration was selected based on preliminary tests.
Concentrations between 0.1 and 1μM were tested, and
higher concentrations stopped the beating completely in
majority of the cells.
4.3. L4115F and V4653F. Point mutations in RYR2 cause gain
of function and spontaneous Ca2+ leakage through the chan-
nel leading to altered Ca2+ handling in CMs. The L4115F and
V4653F mutations in RYR2 are located in the mutation clus-
ters 3 and 4, more precisely in the central and channel
domains of the protein [21]. Consistent with a previous study,
the CPVT cell lines carrying these two mutations were more
similar to each other and closer to control cell line compared
to the cell line carrying exon 3 deletion [11].
The L4115F CPVT CMs had most PA-, LP-, and IP-
type Ca2+ abnormalities. They also had a wider spectrum
of diﬀerent Ca2+ abnormalities after adrenaline exposure
than the others. LP- and IP-type abnormalities could easily
be seen arising from DADs (Figure 3). PA abnormalities
resemble more EADs, which at the plateau or repolariza-
tion phase cause prolongation of Ca2+ transients. LP and
IP abnormalities instead create small upward ﬂuctuations
during diastole, in the baseline of Ca2+ transients. In the
study by Itzhaki and coworkers with a M4109R RYR2
mutant iPSC-derived CMs, DADs in the phase 4 of APs
were the most prevalent arrhythmias seen in patch-clamp
recordings [17]. The two aforementioned mutations
(L4115F and M4109R) are located close to each other in
the RYR2 amino acid sequence, and abnormal transients
caused by them are very similar. Even though the studies
utilized two diﬀerent methods, the mutations may have
similar arrhythmogenic mechanism creating DADs caused
by lowered threshold for SOICR.
A special feature of V4653F CPVT CMs was that they
exhibited alternans (AL) abnormalities, which were truly
extreme, almost caﬀeine-like induced eruptions of Ca2+
from the SR. Those could be a consequence of altered
Ca2+ sensitivity of the RYR2 channel opening. Tryptophan
being an aromatic amino acid, and not the smallest in size
either, could easily be seen creating disruption in tightly
packed central and channel domains of the RYR2 altering
its function. However, it is hard to say without detailed
protein modeling what kind of structural aberrations it
could cause in the RYR2 exactly. One noticeable diﬀerence
in the eﬃcacy of the two studied drugs was the eﬀect of ﬂe-
cainide, and, more precisely, the ineﬃcacy of carvedilol
therapy on these AL-type abnormalities. Besides SR Ca2+
leak, it is also possible that inﬂux of calcium contributes
to this kind of abnormal transients. Therefore, this could
explain the partial inhibition of the abnormalities by both
of the drugs, since even though they have an eﬀect on the
SR calcium leak, they might not be able to aﬀect the Ca2+
inﬂux.
4.4. Exon 3 Deletion. The exon 3 deletion in RYR2 leads to a
severe clinical phenotype of CPVT [22]. The patient carrying
the exon 3 deletion had the most polymorphic ventricular
complexes at rest during ECG compared to patients carrying
L4115F and V4653F mutations [11]. At the protein level,
exon 3 deletion causes a structural defect of the cytosolic part
of the RYR2 in the N-terminal domain aﬀecting domain-
domain interactions inside the protein [21, 22]. Moreover,
the ability of RYR2 to rescue itself from a complete unfolding,
as a consequence of the exon 3 deletion, via a β-strand switch
of a ﬂexible loop region renders it more thermally stable [22].
Compared to the gain of function point mutations in RYR2,
the Ca2+ leak-causing mechanism of exon 3 deletion seems to
be much more complicated. It is thought, even though the
structural changes were caused by exon 3 deletion, that the
allosteric eﬀects to the channel domain would explain the
disease-causing malfunction of the Ca2+ gating [2]. In addi-
tion, the conformational changes, which occur because of
the exon 3 deletion, may result in missing or hidden binding
sites for RYR2 regulators or coactivators. The aforemen-
tioned fundamental diﬀerences between the exon 3 deletion
and the two studied point mutations probably explain the
higher incidence of the more severe OS- and MP-type abnor-
malities in the CPVT CMs carrying exon 3 deletion. The
ﬁnding supports another study, which found the exon 3 dele-
tion of RYR2 to be resulted in abnormal termination of Ca2+
release through the channel [23]. In addition, OS- and M-
type abnormalities had signiﬁcantly higher Ca2+ peak dura-
tion and lower ΔF/F0.
Carvedilol and ﬂecainide were equally eﬀective in CPVT
cell lines. The antiarrhythmic mechanism of these drugs is
based on inhibition of abnormal SR calcium leak and stabi-
lization of [Ca2+]i and therefore suppression of changes in
AP which could generate EADs/DADs. Both carvedilol and
ﬂecainide were the most eﬀective on the CMs carrying
RYR2 exon 3 deletion. Interestingly, the exon 3 deletion is
also associated with a severe clinical phenotype [24]. The
abnormalities caused by the deletion, mostly OS and MP,
were abolished rather well by both drugs. This indicates that
the drugs being eﬀective against the OS- and MP-type
abnormalities could explain the resulting beneﬁt achieved
in the CMS with RYR2 exon 3 deletion.
4.5. Limitations. In this study, we did not diﬀerentiate
between CM subtypes (atrial, nodal, or ventricular). In
addition, iPSC-derived CMs are considered to be function-
ally immature and methods to increase their maturity are
intensively investigated in many research groups. Further-
more, it is still unclear how well the calcium abnormalities
observed in the iPSC CMs mimic the disease mechanism
and whether they predict the treatment eﬃcacy of all
drugs in CPVT patients.
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5. Conclusions
Carvedilol and ﬂecainide were equally eﬀective in treating
arrhythmias in CPVT-speciﬁc iPSC-derived CMs in this
study. However, the proarrhythmic risk of ﬂecainide should
be recognized as it induced arrhythmias in control cells. Even
though the CPVT CMs carrying exon 3 deletion had the most
severe Ca2+ abnormalities, it had the best response to the
drug therapies. Both of these drugs are used in the clinics
for the treatment of CPVT. However, according to this study,
the arrhythmia-abolishing eﬀect of these drugs is not opti-
mal at least at these concentrations. iPSC-derived CMs
provide a unique platform for testing new potential drugs
for CPVT. More detailed studies with combined or simul-
taneous electrophysiological techniques are needed to fully
understand the drug eﬀects and aberrations in excitation
contraction coupling leading to arrhythmias in CPVT dis-
ease modeling.
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Supplementary Materials
The supplementary material to this manuscript includes
detailed description of the materials and methods, additional
hiPSC line characterization, and results supporting the data.
Supplementary Figure 1: characterization of the
UTA.05603.CPVT hiPSC line (exon 3 deletion). Expression
of pluripotency markers Nanog, OCT3/4, SOX2, ssea4, tra1-
60, and tra1-81 was conﬁrmed in embryoid bodies (EB) by
immunocytochemistry. Expression of SOX17, AFP, α-cardiac
actinin, VEGFR/KDR, SOX1, and Pax6 in EBs was conﬁrmed
by PCR. Expression of endogenes Rex1 and β-actinin was
conﬁrmed by PCR. Inactivation of exogenes OCT3/4, SOX2,
KLF4, and c-MYC was conﬁrmed by PCR. Supplementary
Figure 2: karyotype analysis of the UTA.05603.CPVT hiPSC
line (exon 3 deletion). Karyotype was conﬁrmed normal by
PerkinElmer karyolite analysis. Supplementary Figure 3: rep-
resentative calcium traces from each category before and after
the addition of carvedilol. Consecutive traces were recorded
from the same cell. In the presence of 1μM adrenaline,
0.25μM carvedilol caused calcium abnormalities (IP) in
26% of wild-type cells. Responder CPVT had oscillation
(OS) in the baseline and after adrenaline stimulus, but carve-
dilol abolished all these arrhythmias. Semiresponder still had
one multiple-peak event (MP) after carvedilol. In nonre-
sponder, oscillation at baseline and during adrenaline turned
into multiple peaks (MP) after carvedilol. Supplementary
Figure 4: representative calcium traces from each category
before and after the addition of ﬂecainide. Consecutive traces
were recorded from the same cell. In the presence of 1μM
adrenaline, 10μM ﬂecainide caused prolongation of calcium
transients (PA) in 53% of wild-type cells. Responder CPVT
had oscillation (OS) in the baseline and after adrenaline stim-
ulus, but ﬂecainide abolished all these arrhythmias. In semire-
sponder CPVT, oscillation at baseline and after adrenaline
stimulus turned into irregular beating phase (IP). In nonre-
sponder CPVT, ﬂecainide was not able to abolish alternans
(AL) abnormalities. Supplementary Figure 5: comparison of
abnormal calcium peak amplitude (ΔF/F0) and duration to
normal after adrenaline stimulation. (A) ΔF/F0 was signif-
icantly (P < 0 05) lower in CPVT CMs exhibiting OS, MP,
and PA calcium abnormalities compared to normal ones.
(B) Duration was signiﬁcantly (P < 0 05) longer in CPVT
CMs exhibiting OS and MP (but not PA) calcium abnor-
malities compared to normal ones. Supplementary Figure
6: comparison of diﬀerent calcium transient parameters
between responders and nonresponders. (A) CMs with
exon 3 deletion in which carvedilol abolished all calcium
abnormalities had higher ΔF/F0 which indicates [Ca2+]i.
Control CMs in which carvedilol caused arrhythmias had
higher beating frequency, but the ﬁnding was not statistically
signiﬁcant. Control CMs in which ﬂecainide caused arrhyth-
mias had longer calcium peak duration, half-width (C and
D), and lower beating frequency (E) CMs. ϯ indicates statisti-
cal signiﬁcance (P < 0 05). (Supplementary Materials)
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